Neda Mousavi-Niri

Dr. Neda Mousavi-Niri

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2016 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
NKNasim Kheshtchin
Nasim Kheshtchin
SASamaneh Arab
Samaneh Arab
MAMaryam Ajami
Maryam Ajami
RMReza Mirzaei
Reza Mirzaei
MAMahboubeh Ashourpour
Mahboubeh Ashourpour
JHJamshid Hadjati
Jamshid Hadjati

28 March 2017 in Tumor Biology
Verified
Journal Article
Open access
SASamaneh Arab
Samaneh Arab
NKNasim Kheshtchin
Nasim Kheshtchin
MAMaryam Ajami
Maryam Ajami
MAMahbubeh Ashurpoor
Mahbubeh Ashurpoor
ASAida Safvati
Aida Safvati
JHJamshid Hadjati
Jamshid Hadjati
Dendritic cells are important in initiating immune responses; therefore, a range of dendritic cell–based approaches have been established to induce immune response against cancer cells. However, the presence of immunosuppressive mediators such as adenosine in the tumor microenvironment reduces the efficacy of dendritic cell–based cancer immunotherapy. In this study, we investigated whether blockade of the A2A adenosine receptor with a selective antagonist and a CD73 inhibitor may increase the efficacy of a dendritic cell–based cancer vaccine. According to the findings, this therapeutic combination reduced tumor growth, prolonged survival of tumor-bearing mice, and enhanced specific antitumor immune responses. Thus, we suggest that targeting cancer-derived adenosine improves the outcomes of dendritic cell–based cancer immunotherapy.

6 January 2023 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
TPTara Pourseif
Tara Pourseif
RGRobabehbeygom Ghafelehbashi
Robabehbeygom Ghafelehbashi
MAMohammadreza Abdihaji
Mohammadreza Abdihaji
NRNiloufar Radan
Niloufar Radan
EKEhsan Kaffash
Ehsan Kaffash
QRQun Ren
Qun Ren

6 October 2023 in Environmental Research
Verified
Journal Article
Open access
SASahar Amiri
Sahar Amiri
FPFatemeh Pashizeh
Fatemeh Pashizeh
KMKasra Moeinabadi-Bidgoli
Kasra Moeinabadi-Bidgoli
YEYalda Eyvazi
Yalda Eyvazi
TATanin Akbari
Tanin Akbari
Mohammad Tavakkoli YarakiMohammad Tavakkoli Yaraki
Mohammad Tavakkoli Yaraki
Combination therapy has been considered one of the most promising approaches for improving the therapeutic effects of anticancer drugs. This is the first study that uses two different antioxidants in full-characterized niosomal formulation and thoroughly evaluates their synergistic effects on breast cancer cells. In this study, in-silico studies of hydrophilic and hydrophobic drugs (ascorbic acid: Asc and curcumin: Cur) interactions and release were investigated and validated by a set of in vitro experiments to reveal the significant improvement in breast cancer therapy using a co-delivery approach by niosomal nanocarrier. The niosomal nanoparticles containing surfactants (Span 60 and Tween 60) and cholesterol at 2:1 M ratio were prepared through the film hydration method. A systematic evaluation of nanoniosomes was carried out. The release profile demonstrated two phases (initial burst followed by sustained release) and a pH-dependent release schedule over 72 h. The optimized niosomal preparation displayed superior storage stability for up to 2 months at 4 °C, exhibiting extremely minor changes in pharmaceutical encapsulation efficiency and size. Free dual drugs (Asc + Cur) and dual-drug loaded niosomes (Niosomal (Asc + Cur)) enhanced the apoptotic activity and cytotoxicity and inhibited cell migration which confirmed the synergistic effect of co-encapsulated drugs. Also, significant up-regulation of p53 and Bax genes was observed in cells treated with Asc + Cur and Niosomal (Asc + Cur), while the anti-apoptotic Bcl-2 gene was down-regulated. These results were in correlation with the increase in the enzyme activity of SOD, CAT, and caspase, and the levels of MDA and ROS upon treatment with the mentioned drugs. Furthermore, these anti-cancer effects were higher when using Niosomal (Asc + Cur) than Asc + Cur. Histopathological examination also revealed that Niosomal (Asc + Cur) had a lower mitosis index, invasion, and pleomorphism than Asc + Cur. These findings indicated that niosomal formulation for co-delivery of Asc and Cur would offer a promising delivery system for an effective breast cancer treatment.

25 September 2023 in Journal of Biological Engineering
Verified
Journal Article
Open access
PDF file
ABAzar Bakand
Azar Bakand
SMSevil Vaghefi Moghaddam
Sevil Vaghefi Moghaddam
MNMaryam Naseroleslami
Maryam Naseroleslami
HAHelder André
Helder André
NMNeda Mousavi-Niri
Neda Mousavi-Niri
EAEffat Alizadeh
Effat Alizadeh
A number of molecular biofactors have been documented in pathogenesis and poor prognosis of colorectal cancer (CRC). Among them, the Hypoxia-Inducible Factor (HIF-1a) is frequently reported to become over-expressed, and its targeting could restrict and control a variety of essential hallmarks of CRC. Niosomes are innovative drug delivery vehicles with the encapsulating capacity for co-loading both hydrophilic and hydrophobic drugs at the same time. Also, they can enhance the local accumulation while minimizing the dose and side effects of drugs. YC-1 and PX-12 are two inhibitors of HIF-1a. The purpose of this work was to synthesize dual-loaded YC-1 and PX-12 niosomes to efficiently target HIF-1α in CRC, HT-29 cells. The niosomes were prepared by the thin-film hydration method, then the niosomal formulation of YC-1 and PX-12 (NIO/PX-YC) was developed and optimized by the central composition method (CCD) using the Box-Behnken design in terms of size, polydispersity index (PDI), entrapment efficiency (EE). Also, they are characterized by DLS, FESEM, and TEM microscopy, as well as FTIR spectroscopy. Additionally, entrapment efficiency, in vitro drug release kinetics, and stability were assessed. Cytotoxicity, apoptosis, and cell cycle studies were performed after the treatment of HT-29 cells with NIO/PX-YC. The expression of HIF-1αat both mRNA and protein levels were studied after NIO/PX-YC treatment. The prepared NIO/PX-YC showed a mean particle size of 185 nm with a zeta potential of about-7.10 mv and a spherical morphology. Also, PX-12 and YC-1 represented the entrapment efficiency of about %78 and %91, respectively, with a sustainable and controllable release. The greater effect of NIO/PX-YC than the free state of PX-YC on the cell survival rate, cell apoptosis, and HIF-1α gene/protein expression were detected (p < 0.05). In conclusion, dual loading of niosomes with YC-1 and PX-12 enhanced the effect of drugs on HIF-1α inhibition, thus boosting their anticancer effects. Graphical Abstract

1 September 2016 in Journal of Immunotherapy
Verified
Journal Article
Closed access
NMNeda Mousavi-Niri
Neda Mousavi-Niri
AMArash Memarnejadian
Arash Memarnejadian
YPYounes Pilehvar-Soltanahmadi
Younes Pilehvar-Soltanahmadi
MSMohammadreza Agha Sadeghi
Mohammadreza Agha Sadeghi
MMMehdi Mahdavi
Mehdi Mahdavi
JHJamshid Hajati
Jamshid Hajati
Introduction: The critical role of regulatory T (Treg) cells in dampening immune responses against tumor cells is apparent. Therefore, several methods have been introduced for eliminating Treg. Among them, inducing immune responses against Treg cells expressing Foxp3 transcription factor is a hopeful approach to decrease the frequency of Tregs. In current study, we used the chimeric FoxP3-Fc(IgG) fusion construct/protein to effectively stimulate the immune responses against Treg cells. Materials and Methods: Previously constructed FoxP3-Fc(IgG) DNA vaccine and its protein counterpart were injected into C57BL/6 mice in a prime/boost regimen. After 2 weeks, the mice were killed to measure the frequency of Tregs in their spleens, as well as analyze their specific cytokine production, T-cell proliferation, and CD8+ T-cell cytotoxicity against FoxP3 protein. Results: FACS analysis of FoxP3+ CD4+ cells in splenocytes revealed the efficiency of FoxP3 DNA-prime protein-boost strategy to decrease the Treg cells and further showed considerable superiority of Fc(IgG) fusion strategy. This significant reduction in Treg frequency was also concomitant with higher FoxP3-specific CTL and Th1 responses in FoxP3-Fc vaccinated animals. Conclusions: Prime/boost vaccination against FoxP3 in addition to enhanced antigen presentation by means of Fc fusion strategy could be successfully considered for Treg depletion studies. Validity of this approach should be experimentally tested in preclinical tumor models.